Prediction of Survival of HPV16-Negative, p16-Negative Oral Cavity Cancer Patients Using a 13-Gene Signature: A Multicenter Study Using FFPE Samples

Details

• Personal Author:
  Abedi-Ardekani B ; Agudo A ; Ahrens W ; Alemany L ; Anantharaman D ; Brennan P ; Chen C ; Conway DI ; Dort JC ; Futran ND ; Günther K ; Hansen BT ; Hashibe M ; Healy CM ; Holcatova I ; Houck JR ; Itani D ; Kjaerheim K ; Lohavanichbutr P ; Monroe MM ; Nakoneshny S ; Peterson LA ; Rozek LS ; Schwartz SM ; Thomson PJ ; Upton MP ; Wang P ; Witt BL ; Wolf G ; Zarins KR ; Zhang Y
• Description:
  Objectives: To test the performance of an oral cancer prognostic 13-gene signature for the prediction of survival of patients diagnosed with HPV-negative and p16-negative oral cavity cancer. Materials and Methods: Diagnostic formalin-fixed paraffin-embedded oral cavity cancer tumor samples were obtained from the Fred Hutchinson Cancer Research Center/University of Washington, University of Calgary, University of Michigan, University of Utah, and seven ARCAGE study centers coordinated by the International Agency of Research on Cancer. RNA from 638 Human Papillomavirus (HPV)-negative and p16-negative samples was analyzed for the 13 genes using a NanoString assay. Ridge-penalized Cox regressions were applied to samples randomly split into discovery and validation sets to build models and evaluate the performance of the 13-gene signature in predicting 2-year oral cavity cancer-specific survival overall and separately for patients with early and late stage disease. Results: Among AJCC stage I/II patients, including the 13-gene signature in the model resulted in substantial improvement in the prediction of 2-year oral cavity cancer-specific survival. For models containing age and sex with and without the 13-gene signature score, the areas under the Receiver Operating Characteristic Curve (AUC) and partial AUC were 0.700 vs. 0.537 (p < 0.001), and 0.046 vs. 0.018 (p < 0.001), respectively. Improvement in predicting prognosis for AJCC stage III/IV disease also was observed, but to a lesser extent. Conclusions: If confirmed using tumor samples from a larger number of early stage oral cavity cancer patients, the 13-gene signature may inform personalized treatment of early stage HPV-negative and p16-negative oral cavity cancer patients. [Description provided by NIOSH]
• Subjects:
  Delivery Of Health Care Genetics Neoplasms Occupational Health Safety
• Keywords:
  Author Keywords: Oral Cancer Cancer Genes Genetic Testing HPV Medical Care Oral Cancer Oral Cavity Oral Cavity Cancer P16 Prognosis Prognostic Gene Signature Survival Rate

  More +
• ISSN:
  1368-8375
• Document Type:
  Text
• Funding:
  Grant
• Genre:
  Journal Article
• Place as Subject:
  Michigan ; New York ; OSHA Region 10 ; OSHA Region 2 ; OSHA Region 5 ; OSHA Region 8 ; Utah ; Washington
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Volume:
  100
• NIOSHTIC Number:
  nn:20059188
• Citation:
  Oral Oncol 2020 Jan; 100:104487
• Contact Point Address:
  Chu Chen, Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Mailstop M5-C800, 1100 Fairview Ave N, Seattle, WA 98109-1024, USA
• Email:
  cchen@fredhutch.org
• Federal Fiscal Year:
  2020
• Performing Organization:
  University of Michigan, Ann Arbor
• Peer Reviewed:
  True
• Start Date:
  20050701
• Source Full Name:
  Oral Oncology
• End Date:
  20280630
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:269f09229aaa6e63e80629bae5931e1f70dd0a369a05a12199bcb01d6c0331f4fe05cf614444816ea367b3ebb0f019437af5d33e682e1c1e9617bf85e82828e0
• Download URL:
  https://stacks.cdc.gov/view/cdc/223482/cdc_223482_DS1.pdf
• File Type:
  [PDF - 809.21 KB ]